{
    "id": "wrong_mix_random_publicationDate_00090_2",
    "rank": 85,
    "data": {
        "url": "https://www.nature.com/articles/nbt1298_1376",
        "read_more_link": "",
        "language": "en",
        "title": "PEOPLE",
        "top_image": "https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2F4365/MediaObjects/41587_1998_Article_BFnbt1298_1376_Figa_HTML.jpg",
        "meta_img": "https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2F4365/MediaObjects/41587_1998_Article_BFnbt1298_1376_Figa_HTML.jpg",
        "images": [
            "https://pubads.g.doubleclick.net/gampad/ad?iu=/285/biotech.nature.com/article&sz=728x90&c=1068836699&t=pos%3Dtop%26type%3Darticle%26artid%3Dnbt1298_1376%26doi%3D10.1038/4365%26kwrd%3DLife+Sciences%2C+general,Biotechnology,Biomedicine%2C+general,Agriculture,Biomedical+Engineering%2FBiotechnology,Bioinformatics",
            "https://media.springernature.com/full/nature-cms/uploads/product/nbt/header-8f661e82c86879a1b8f03cbd053d5155.svg",
            "https://media.springernature.com/relative-r300-703_m1050/springer-static/image/art%3A10.1038%2F4365/MediaObjects/41587_1998_Article_BFnbt1298_1376_Figa_HTML.jpg",
            "https://media.springernature.com/relative-r300-703_m1050/springer-static/image/art%3A10.1038%2F4365/MediaObjects/41587_1998_Article_BFnbt1298_1376_Figb_HTML.jpg",
            "https://pubads.g.doubleclick.net/gampad/ad?iu=/285/biotech.nature.com/article&sz=300x250&c=-146000458&t=pos%3Dright%26type%3Darticle%26artid%3Dnbt1298_1376%26doi%3D10.1038/4365%26kwrd%3DLife+Sciences%2C+general,Biotechnology,Biomedicine%2C+general,Agriculture,Biomedical+Engineering%2FBiotechnology,Bioinformatics",
            "https://www.nature.com/static/images/logos/sn-logo-white-ea63208b81.svg",
            "https://www.nature.com/static/images/logos/nature-briefing-logo-n150-white-d81c9da3ec.svg",
            "https://verify.nature.com/verify/nature.png",
            "https://www.nature.com/91jpl6kj/article/nbt1298_1376"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": "1998-12-22T00:00:00",
        "summary": "",
        "meta_description": "",
        "meta_lang": "en",
        "meta_favicon": "/static/images/favicons/nature/apple-touch-icon-f39cb19454.png",
        "meta_site_name": "Nature",
        "canonical_link": "https://www.nature.com/articles/nbt1298_1376",
        "text": "Argonex (Charlottesville, VA) has named J. Mark Braughler president and Ramila Philip vice president, immunology and clinical affairs. Most recently, Dr. Braughler was vice president, business development at Pharmacia & Upjohn, and Dr. Philip served as RPR Gencell's senior director of discovery research. Sheridan G. Snyder, Argonex's previous president, will remain as CEO.\n\nSteven Burke has been named as chief financial officer of Techniclone (Tustin, CA), replacing Elizabeth Gorbett-Frost. For the past 12 years he has served as chief financial officer and vice president, finance and administration for Quidel Corp.\n\nHyseq (Sunnyvale, CA) has announced the retirement of board member Radomir B. Crkvenjakov. Dr. Crkvenjakov joined the company in August 1994 as a co-senior vice president for research and development. He will continue to consult with Hyseq and will remain as a member of its scientific advisory board.\n\nLeslie Garrison has been appointed Immunex's (Seattle, WA) vice president, clinical development. Since joining the company in 1989, Dr. Garrison has held several positions within the clinical research department, most recently serving as medical director in charge of the Enbrel (etanercept) clinical program.\n\nAVAX Technologies (Kansas City, MO) has named Judith Ann Hemberger senior vice president of business development, a new post. Dr. Hemberger most recently held the position of senior vice president of worldwide regulatory affairs for Hoechst Marion Rousell.\n\nSUGEN (South San Francisco, CA) has named James L. Knighton to the position of senior vice president and CFO. From 1994 to 1998, Mr. Knighton served in various positions at Chiron, including vice president, strategic operations for the therapeutics division and most recently as vice president, investor relations and corporate communications.\n\nGuilford Pharmaceuticals (Baltimore, MD) has appointed Nancy J. Linck , former solicitor of the US Patent and Trademark Office, to vice president, intellectual property, a newly created position. At the PTO, Dr. Linck also acted as general counsel to Bruce A. Lehman, the Assistant Secretary of Commerce and Commissioner of Patents and Trademarks.\n\nRobert D. Love has been appointed vice president of finance and acquisitions at Innovex (Parsippany, NJ), a division of Quintiles Transnational Corp. Mr. Love has spent the past 19 years with SmithKline Beecham, where he held senior-level positions in finance, business development, and strategic marketing.\n\nTularik has named Corinne H. Lyle as CFO. Ms. Lyle comes to Tularik from Warburg Dillon Read, where she most recently served as an executive director, with responsibility for the company's West Coast healthcare effort.\n\nKenneth M. Merz, Jr. has been named senior director of the Center for Informatics and Drug Discovery (CIDD). Located in Princeton, NJ, The CIDD is a joint research effort between Pharmacopeia (Princeton, NJ) and its subsidiary, Molecular Simulations (San Diego, CA). Dr. Merz is a professor of chemistry at The Pennsylvania State University.\n\nGenelabs Technologies (Redwood City, CA) has announced the appointment of Rich B. Meyer, Jr., as vice president, research. Dr. Meyer most recently was vice president, R&D of Epoch Pharmaceuticals.\n\nClinTrials Research (Nashville, TN) has appointed S. Colin Neill senior vice president and CFO. Before joining the company, Mr. Neill was vice president, CFO of Continental Health Affiliates and acting vice president, finance and CFO of Pharmos Corp.\n\nCephalon (West Chester, PA) has announced the promotion of John E. Osborn to senior vice president, legal, and assistant secretary of the company. Mr. Osborn joined Cephalon in 1997 as vice president and associate general counsel.\n\nGenometrix (The Woodlands, TX) has appointed Bruce Peacock to its board of directors. Mr. Peacock currently serves as executive vice president, COO, and as a member of the board of Cephalon."
    }
}